Centre for Probe Development and Commercialization Project
Molecular imaging enables physicians to visualize non-invasively the biochemical changes in cells that lead to cancer growth and drug resistance, and that help them decide the best course of therapy and assess how well treatments are working. Molecular imaging relies on access to probes that are drug like substances, which seek out these biochemical changes and pathways and makes them visible when a patient is scanned on an imaging instrument such as an MRI or PET machine. This revolutionary technology has the ability to enable earlier disease detection and to help select the right treatment for the right patient at the right time, which ultimately improves outcomes and decreases the ever rising costs of healthcare.
With the support of OICR, scientists across the province are developing the next generation of probes. Unfortunately, there is gap between discoveries made in the lab and the use of the agents to help patients. The CPDC has the projects needed to form a bridge between discovery research done in Ontario and the healthcare providers who want access to the technologies. The CPDC projects also enable Ontario physicians to access agents that are developed and used in other countries, and to participate in national and international efforts to develop and evaluate new generations of probes. These initiatives improve healthcare, reduce costs and help get Canadian discoveries out to the global community.
- Enabling High Quality Cancer Imaging Trials in Ontario;
- Investigator Sponsored Research Projects (ISRP) Program: Driving the Translation and Commercialization of New MI Probes;
- Nationalizing and Internationalizing Ontario MI Probe Know-How;
- The Development of New MI Probes.
Lead Principal Investigator
Dr. John F. Valliant, McMaster University